Merck Group total revenues rose 13% in the first quarter to EUR 2,099 million from EUR 1,859 million in the year-ago quarter as the Chemicals divisions returned to their pre-crisis levels and the Merck Serono prescription drugs division continued on its growth path.
Royalty and commission income declined 25% to EUR 76 million in the first quarter as patents began expiring in some markets on out-licensed products. As revenues increased at a faster rate than production costs, the gross margin rose 15% to EUR 1,612 million from EUR 1,402 million.
|
Components of growth by division – Q1 |
XLS | ||||
|
|
|
|
|
|
|
|
Change in total revenues |
Merck Serono |
Consumer Health Care |
Liquid Crystals |
Performance & Life Science Chemicals |
Merck Group |
|
Organic growth |
7.7 |
–0.5 |
84.7 |
11.3 |
13.2 |
|
Currency effects |
–0.7 |
0.5 |
–2.6 |
0.9 |
–0.5 |
|
Acquisitions/divestitures |
– |
– |
– |
1.1 |
0.2 |
|
Total |
7.0 |
– |
82.1 |
13.3 |
12.9 |